At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 21 enrolled
Drug / intervention
lonafarnib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Dose-ranging, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Lonafarnib With and Without Ritonavir Boosting in Patients Chronically Infected With Delta Hepatitis (HDV) (LOWR-1)
In Brief
A Phase 2 clinical trial evaluating lonafarnib, peginterferon alfa-2a, and 1 other intervention for Chronic Hepatitis D Infection. Completed, enrolled 21 participants across 1 site.
Detailed Summary
To Evaluate the Safety and Efficacy of Lonafarnib with and without Ritonavir Boosting in Adults With Genotype 1 Chronic Hepatitis D Virus (HDV) Infection (LOWR-1).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hepatitis D Infection
CountriesTurkey (Türkiye)
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartNov 2014
First PostedApr 2015
Primary CompletionSep 2015
Study CompletionNov 2015
TodayJul 2026
First PostedApr 30, 2015
Enrollment StartNov 1, 2014
Primary CompletionSep 1, 2015
Study CompletionNov 1, 2015
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 11.2 years ago
Interventions
lonafarnibdrug
antiviral farnesyl transferase inhibitor
peginterferon alfa-2adrug
immunomodulator
ritonavirdrug
CYP 3A4 inhibitor, lonafarnib booster